11,508 results match your criteria Nephritis Lupus


Long Non-Coding RNAs as New Biomarkers in Lupus Nephritis: A Connection Between Present and Future.

Cureus 2020 Jul 5;12(7):e9003. Epub 2020 Jul 5.

Biochemistry, Molecular Medicine and Nutrigenomics, Medical University of Varna, Varna, BGR.

Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE). LN often leads to kidney failure, affecting the quality of a patient's life. There are several classical biomarkers that assist nephrologists' daily practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.9003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402529PMC

Posttransplant Intrarenal Lymphangiectasia.

Case Rep Transplant 2020 21;2020:8824833. Epub 2020 Jul 21.

Division of Interventional Radiology, Department of Radiology, University of Illinois, College of Medicine, Chicago, IL, USA.

Renal lymphangiectasia is an extremely rare benign condition in the setting of transplanted kidneys. We describe a 50-year-old female with a past medical history of lupus nephritis and renal transplants who presented with right lower quadrant pain and was found to have intrarenal lymphangiectasia on imaging and laboratory tests. The patient was treated with percutaneous drainage initially and then wide peritoneal fenestration and omentoplasty. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/8824833DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391098PMC

Pediatric lupus nephritis - An evil cousin of its adult counterpart: A single-center based experience from a tertiary care hospital of Eastern India.

Indian J Pathol Microbiol 2020 Jul-Sep;63(3):397-404

Director, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.

Context: Systemic lupus erythematosus is an autoimmune multisystem disease with a high predilection for renal involvement. Lupus nephritis develops in 20% to 75% within the first two years. Presentation varies from subnephrotic proteinuria to end-stage renal disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPM.IJPM_995_19DOI Listing

FcγRIIA expression aggravates nephritis and increases platelet activation in systemic lupus erythematosus in mice.

Blood 2020 Aug 7. Epub 2020 Aug 7.

CHU de Quebec, Quebec, Quebec, Canada.

Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease characterized by deposits of immune complexes (IC) in organs and tissues. The expression of FcγRIIA by human platelets, which is their unique receptor for IgG antibodies, positions them to ideally respond to circulating IC. Whereas chronic platelet activation and thrombosis are well-recognized features of human SLE, the exact mechanisms underlying platelet activation in SLE are still unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020004974DOI Listing

Population pharmacokinetics model and initial dose optimization of tacrolimus in children and adolescents with lupus nephritis based on real-world data.

Exp Ther Med 2020 Aug 30;20(2):1423-1430. Epub 2020 May 30.

Department of Pharmacy, Children's Hospital of Fudan University, Shanghai 201102, P.R. China.

The present study aimed to establish a population pharmacokinetics model of tacrolimus and further optimize the initial dosing regimen of tacrolimus in pediatric and adolescent patients with lupus nephritis (LN). Pediatric and adolescent patients with LN were recruited between August 2014 and September 2019 at the Children's Hospital of Fudan University (Shanghai, China). Relevant information was used to set up a population pharmacokinetics model with a Nonlinear Mixed Effect Model and the initial dosage regimen was simulated with the Monte Carlo method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2020.8821DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388563PMC

CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.

Arthritis Rheumatol 2020 Aug 4. Epub 2020 Aug 4.

Yale University School of Medicine, Dept. of Medicine, Section of Rheumatology, New Haven, Connecticut, USA.

Objectives: To assess safety and mechanism of action, and generate preliminary efficacy data on rituximabfollowed by belimumab for refractory lupus nephritis.

Methods: Forty three participants with recurrent or refractory lupus nephritis were treated with rituximab, cyclophosphamide, and glucocorticoids, followed by randomization to belimumab infusions (RCB) until Week 48, or no infusion (RC) in a multicenter, randomized, open label clinical trial. Patients were followed until Week 96. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.41466DOI Listing

B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice.

Front Med (Lausanne) 2020 9;7:316. Epub 2020 Jul 9.

Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

B cell hyperactivity and breach of tolerance constitute hallmarks of systemic lupus erythematosus (SLE). The heterogeneity of disease manifestations and relatively rare prevalence of SLE have posed difficulties in trial design and contributed to a slow pace for drug development. The anti-BAFF monoclonal antibody belimumab is still the sole targeted therapy licensed for SLE, lending credence to the widely accepted notion that B cells play central roles in lupus pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2020.00316DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381321PMC

Cardiovascular System Affection and Its Relation to First-Year Mortality in Patients Initiating Maintenance Hemodialysis.

Int J Gen Med 2020 9;13:379-385. Epub 2020 Jul 9.

Internal Medicine Department, Faculty of Medicine, Al-Azhar University for Girls, Cairo, Egypt.

Background: The incidence of end-stage renal disease (ESRD) has increased by 30-40% in the last decade. These patients have a higher mortality rate of 3-8 times compared to the general population. In the present study, we aimed to detect cardiovascular complications and their relation to the first-year mortality rate in patients on hemodialysis in Aswan University Hospital, upper Egypt. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJGM.S242549DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358085PMC

Outcome of patients with lupus nephritis under long-term immunonephrological care

Orv Hetil 2020 08;161(31):1293-1301

I. Belgyógyászat, Nephrológia és Gasztroenterológia Osztály,Péterfy Kórház-Rendelőintézet és Manninger Jenő Országos Traumatológiai Intézet, Budapest, Péterfy S. u. 8-20., 1076.

Introduction: Lupus nephritis is the most severe complication of systemic lupus erythematosus (SLE), its development and the effectiveness of immunosuppressive therapy substantially influence patients' quality of life and survival.

Aim: In this retrospective observational investigation, the long term-outcome of patients with lupus nephritis, followed at the St. Margit Hospital Immunonephrological Outpatient Clinic, was evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1556/650.2020.31801DOI Listing

Severe abdominal pain in a case with lupus nephritis: Answers.

Pediatr Nephrol 2020 Aug 4. Epub 2020 Aug 4.

Department of Pediatrics, Division of Nephrology, Izmir Tepecik Training and Research Hospital, University of Health Sciences, Izmir, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00467-020-04675-4DOI Listing

Severe abdominal pain in a case with lupus nephritis: Questions.

Pediatr Nephrol 2020 Aug 4. Epub 2020 Aug 4.

Department of Pediatrics, Division of Nephrology, Izmir Tepecik Training and Research Hospital, University of Health Sciences, Izmir, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00467-020-04670-9DOI Listing

Urinary biomarkers in lupus nephritis.

J Transl Autoimmun 2020 13;3:100042. Epub 2020 Feb 13.

GIRAT: Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional, Fundación Valle Del Lili and Universidad Icesi, Cali, Colombia.

Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease that can affect any organ of the body. Multiple mechanisms may contribute to the pathophysiology of systemic lupus, including failure to remove apoptotic bodies, hyperactivity of self-reactive B and T lymphocytes, abnormal exposure to autoantigens, and increased levels of B-cell stimulatory cytokines. The involvement of the kidney, called lupus nephritis (LN), during the course of the disease affects between 30% and 60% of adult SLE patients, and up to 70% of children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtauto.2020.100042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388339PMC
February 2020

Expression of BAFF, APRIL, and cognate receptor genes in lupus nephritis and potential use as urinary biomarkers.

J Transl Autoimmun 2020 17;3:100027. Epub 2019 Dec 17.

GIRAT: Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional; Fundación Valle Del Lili and Universidad Icesi, Cali, Colombia.

Background: B-cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), and their receptors BAFF-R, BCMA, and TACI are crucial factors for the survival of B lymphocytes. Recent evidence has also demonstrated the importance of BAFF/APRIL signaling in lupus nephritis (LN). This study evaluated the relationships between LN clinical characteristics and the urinary expression levels of BAFF, APRIL, and cognate receptors to assess their potential value as disease biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtauto.2019.100027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388398PMC
December 2019

Hydralazine-Induced Dual Antineutrophil Cytoplasmic Antibody Positive Vasculitis and Nephritis.

Cureus 2020 Jun 29;12(6):e8911. Epub 2020 Jun 29.

Nephrology, Augusta University Medical College of Georgia, Augusta, USA.

Drug-induced autoimmunity occurs when exposure to a causative agent leads to serologic or clinical autoimmune responses. Syndromes that may be associated with drug-induced autoimmunity include antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) and drug-induced lupus (DIL). When drug-induced autoimmunity involves the kidney, histological patterns of injury include pauci-immune glomerulonephritis (GN), which occurs with AAV, and immune complex-mediated GN, which is associated with DIL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8911DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389885PMC

Characteristics of lupus nephritis in Saudi lupus patients: A retrospective observational study.

Lupus 2020 Aug 2:961203320947151. Epub 2020 Aug 2.

Rheumatology Section, Medical Specialties Department, King Fahad Medical City, Riyadh, Saudi Arabia.

Objectives: Systemic lupus erythematosus (SLE) is a chronic autoimmune multi-systemic disorder of the connective tissue, characterized mainly by involvement of the skin, joints, kidneys, and serosal membranes. It affects females particularly at childbearing age more commonly than males. Lupus nephritis affects around half of patients with SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203320947151DOI Listing

Maternal and fetal outcomes of lupus pregnancies: A collective effort by Karnataka Rheumatologists.

Lupus 2020 Aug 2:961203320944503. Epub 2020 Aug 2.

Department of Clinical Immunology and Rheumatology, St John's Medical College Hospital, Bengaluru, India.

Introduction: Identifying factors predicting adverse pregnancy outcomes involving systemic lupus erythematosus (SLE) is a research priority. The aims of this study were to investigate (a) the maternal and fetal outcomes of pregnant lupus patients and the factors associated with adverse pregnancy outcomes, and (b) the effect of pregnancy on lupus disease activity of these patients.

Methods: This was an ambi-directional study collecting information from five multi-specialist referral centres across the state of Karnataka, India over 5 years (2013-2018). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203320944503DOI Listing

Cachexia in Systemic Lupus Erythematosus: Risk Factors and Relation to Disease Activity and Damage.

Arthritis Care Res (Hoboken) 2020 Aug 2. Epub 2020 Aug 2.

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Objective: Cachexia is a disorder characterized by involuntary weight loss in addition to loss of homeostatic control of both energy and protein balance. Despite an abundance of data from other inflammatory diseases, cachexia in SLE remains a largely undescribed syndrome.

Methods: 2406 patients in a prospective SLE cohort had their weight assessed at each visit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.24395DOI Listing

Effects of AS2819899, a novel selective PI3Kδ inhibitor, in a NZB/W F1 mouse lupus-like nephritis model.

Int Immunopharmacol 2020 Jul 28;87:106764. Epub 2020 Jul 28.

Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.

Phosphoinositide 3-kinases generate lipid-based second messengers that control an array of intracellular signaling pathways. In particular, phosphoinositide 3-kinases delta (PI3Kδ) is expressed primarily in hematopoietic cells and plays an important role in B-cell development and function. B cells play a critical role in autoimmune diseases by producing autoantibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2020.106764DOI Listing

Hydralazine induced lupus nephritis after prolonged exposure.

Am J Med Sci 2020 Jul 7. Epub 2020 Jul 7.

Department of Internal Medicine, Lincoln Medical Center, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjms.2020.07.007DOI Listing

Lupus nephritis in a transgender woman on cross-sex hormone therapy: a case for the role of oestrogen in systemic lupus erythematosus.

Lupus 2020 Jul 30:961203320946372. Epub 2020 Jul 30.

Department of Internal Medicine, Brookwood Baptist Health Birmingham, Alabama, USA.

We present the case of a 22-year-old African American transgender women (male to female), who was admitted for fatigue, abdominal pain and lower extremity edema and was diagnosed with systemic lupus erythematosus (SLE) and lupus nephritis. Treatment with high-dose steroids and mycophenolate mofetil helped resolve her symptoms. She has remained off oestrogen therapy since admission and has not experienced any major complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203320946372DOI Listing

Detection of water-molecular-motion configuration in patients with lupus nephritis: a primary study using diffusion-weighted imaging.

BMC Nephrol 2020 Jul 29;21(1):313. Epub 2020 Jul 29.

Department of Nephrology, Tianjin Medical University General Hospital, No.154 Anshan Road, Heping District, Tianjin, China.

Background: Lupus nephritis (LN) is one of most common types of secondary glomerulonephritis, which is characterized by longitudinal pathological changes. Microstructural lesions of LN will impact the motion of water molecules, which can be detected by diffusion-weighted imaging (DWI). There are few reported measurements of water diffusion in patients with LN, and the nature of water diffusion across the entire depth of the renal parenchyma remains largely unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12882-020-01955-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392731PMC

Kidney outcomes for children with lupus nephritis.

Pediatr Nephrol 2020 Jul 28. Epub 2020 Jul 28.

Department of Paediatric Nephrology, Great Ormond Street NHS Foundation Trust Hospital, London, UK.

Systemic lupus erythematosus is a rare lifelong multi-systemic autoimmune condition. Juvenile-onset SLE (JSLE) is recognized to have a more active disease course when compared with adult-onset disease and patients have a worse long-term survival. Kidney involvement occurs in over 50% of children and treatment decisions are guided by the histological classification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00467-020-04686-1DOI Listing

Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment.

RMD Open 2020 Jul;6(2)

Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Background: Approximately 30% of patients with the systemic autoimmune/inflammatory disorder systemic lupus erythematosus (SLE) develop lupus nephritis (LN) that affects treatment and prognosis. Easily accessible biomarkers do not exist to reliably predict renal disease. The Maximizing SLE Therapeutic Potential by Application of Novel and Systemic Approaches and the Engineering Consortium aims to identify indicators of treatment responses in SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2020-001257DOI Listing

Bacteroides fragilis alleviates the symptoms of lupus nephritis via regulating CD1d and CD86 expressions in B cells.

Eur J Pharmacol 2020 Jul 25;884:173421. Epub 2020 Jul 25.

The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, 210093, PR China; Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, PR China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing, 210093, PR China. Electronic address:

Emerging evidences indicated that the dysbiosis of microbiota was related to the onset of systemic lupus erythematosus (SLE). Bacteroides fragilis (B. fragilis) ATCC 25285, a human commensal, was discovered to improve inflammatory diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2020.173421DOI Listing

Independent Replication on Genome-Wide Association Study Signals Identifies as a Novel Locus for Systemic Lupus Erythematosus.

Front Genet 2020 3;11:600. Epub 2020 Jul 3.

Department of Pediatrics, Union Hospital Affiliated to Fujian Medical University, Fuzhou, China.

Systemic lupus erythematosus (SLE) is a genetically complex autoimmune disease. Despite the significant progress made in identifying susceptibility genes for SLE, the genetic architecture of the disease is far from being understood. In this study, we set to replicate a number of suggestive association signals found in genome-wide association studies (GWASs) in additional independent cohorts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fgene.2020.00600DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348047PMC

Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients with Systemic Lupus Erythematosus.

Arthritis Rheumatol 2020 Jul 26. Epub 2020 Jul 26.

Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY, USA.

Objective: To characterize patients with Systemic Lupus Erythematosus (SLE) affected by COVID-19 and to analyze associations of comorbidities and medications on infection outcomes.

Methods: Patients with SLE and RT-PCR-confirmed COVID-19 were identified through an established New York University lupus cohort, query of two hospital systems, and referrals from rheumatologists. Data were prospectively collected via a web-based questionnaire and review of medical records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.41450DOI Listing

LncRNA NEAT1 accelerates renal mesangial cell injury via modulating the miR-146b/TRAF6/NF-κB axis in lupus nephritis.

Cell Tissue Res 2020 Jul 24. Epub 2020 Jul 24.

Department of Rheumatology and Immunology, Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), No.89, Guhan Road, Furong District, Changsha, 410016, Hunan Province, People's Republic of China.

Although growing advances have been made in the regulation of lupus nephritis recently, lupus nephritis is still one of the major causes of death in SLE patients and the pathogenesis remains largely unknown. Therefore, exploring the pathological mechanisms is urgently needed for designing and developing novel therapeutic strategies for lupus nephritis. Human renal mesangial cells (HRMCs) were transfected with sh-NEAT1, miR-146b mimic, pcDNA-NEAT1, miR-146b inhibitor, or sh-TRAF6 to modify their expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00441-020-03248-zDOI Listing

Effectiveness of Bailing capsules in the treatment of lupus nephritis: A meta‑analysis.

Mol Med Rep 2020 Sep 30;22(3):2132-2140. Epub 2020 Jun 30.

Department of Nephrology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Previous studies have explored the treatment of lupus nephritis with Bailing capsules; however, due to limited sample sizes and inconsistent results across these studies, no definitive conclusions have been drawn. Thus, the present study aimed to provide evidence for the effectiveness of Bailing capsules in the treatment of lupus nephritis. To obtain relevant clinical studies (published before 20 July 2019), PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, WanFang and the Chinese Biomedical Literature Database were searched, and relevant studies concerning the use of Bailing capsules for treating lupus nephritis were selected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mmr.2020.11293DOI Listing
September 2020

Unusual presentation of fatal disseminated varicella zoster virus infection in a patient with lupus nephritis: a case report.

BMC Infect Dis 2020 Jul 23;20(1):538. Epub 2020 Jul 23.

Department of Translational Medicine, DiMet, Università del Piemonte Orientale, via Solaroli 17, 28100, Novara, Italy.

Background: The risk of life-threatening complications, such as visceral disseminated varicella zoster virus (VZV) infection, is greater in immunosuppressed individuals, such as systemic lupus erythematosus (SLE) patients.

Case Presentation: Here, a case is reported of a Caucasian woman diagnosed with lupus nephritis and anti-phospholipid syndrome, who was subjected to mycophenolate mofetil and high-dose steroid remission-induction therapy. Two months later she developed abdominal pain followed by a fatal rapid multi-organ failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12879-020-05254-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376941PMC

Caffeine intake influences disease activity and clinical phenotype in systemic lupus erythematosus patients.

Lupus 2020 Jul 23:961203320941920. Epub 2020 Jul 23.

Lupus Clinic, Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.

Objective: Caffeine, one of the most widely consumed products in the world, seems to interact with multiple components of the immune system by acting as a non-specific phosphodiesterase inhibitor. In vitro dose-dependent treatment with caffeine down-regulates mRNA levels of key inflammation-related genes in peripheral blood mononuclear cells. So far, no robust data are available about the possible contribution of caffeine in systemic lupus erythematosus (SLE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203320941920DOI Listing

Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations.

RMD Open 2020 Jul;6(2)

Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, General University Hospital Attikon, Athens, Greece.

Objectives: To analyse the current evidence for the management of lupus nephritis (LN) informing the 2019 update of the EULAR/European Renal Association-European Dialysis and Transplant Association recommendations.

Methods: According to the EULAR standardised operating procedures, a PubMed systematic literature review was performed, from January 1, 2012 to December 31, 2018. Since this was an update of the 2012 recommendations, the final level of evidence (LoE) and grading of recommendations considered the total body of evidence, including literature prior to 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2020-001263DOI Listing

Comparison of complete renal response and mortality in early- and late-onset lupus nephritis: a multicenter retrospective study of a Japanese cohort.

Arthritis Res Ther 2020 Jul 22;22(1):175. Epub 2020 Jul 22.

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Background: Most patients with systemic lupus erythematosus (SLE) progress to lupus nephritis (LN) within 5 years of their SLE diagnosis, although it is not uncommon for LN to develop at later time points. Here we evaluated the clinical features of early- and late-onset LN.

Patients And Methods: We retrospectively analyzed the cases of 184 of the 201 patients who underwent a renal biopsy at Nagasaki University Hospital and associated community hospitals between 1990 and 2016 and were diagnosed as having LN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-020-02271-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374914PMC

Correlation between C-reactive Protein with Malondialdehyde in Systemic Lupus Erythematosus Patients.

Int J Rheumatol 2020 1;2020:8078412. Epub 2020 Jul 1.

Lupus Study Centre, Immunology Study Group, Padjadjaran University/Hasan Sadikin Hospital, Bandung, West Java, Indonesia.

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by an inflammatory process. One of the inflammation markers that can be measured is C-reactive protein (CRP). Another indicator of inflammation is malondialdehyde (MDA), though it is still uncommon to be analyzed in SLE patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/8078412DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350173PMC

Comparison of treatment response and serious infection of tacrolimus, tacrolimus with mycophenolate mofetil, in comparison to cyclophosphamide as induction treatment for lupus nephritis
.

Int J Clin Pharmacol Ther 2020 Jul 21. Epub 2020 Jul 21.

Aims: This study evaluated the relative efficacy and safety of tacrolimus, tacrolimus+mycophenolate mofetil (MMF), and cyclophosphamide (CYC) for lupus nephritis.

Materials And Methods: Randomized controlled trials (RCTs) were included to investigate the effectiveness and safety of tacrolimus, tacrolimus+MMF, and CYC as a lupus induction therapy. We performed a Bayesian network meta-analysis of the random effects to incorporate direct and indirect data from RCTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5414/CP203736DOI Listing

Elevated Urinary Neutrophil Gelatinase-Associated Lipocalin Is a Biomarker for Lupus Nephritis: A Systematic Review and Meta-Analysis.

Biomed Res Int 2020 30;2020:2768326. Epub 2020 Jun 30.

Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine, Nanjing 210009, China.

Objective: Lupus nephritis (LN) is a major and severe complication of systemic lupus erythematosus (SLE). Neutrophil gelatinase-associated lipocalin (NGAL), as a promising next-generation biomarker in clinical nephrology, has received extensive attention. However, its diagnostic performance in LN has high variability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/2768326DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346103PMC

Patient-reported flare frequency is associated with diminished quality of life and family role functioning in systemic lupus erythematosus.

Qual Life Res 2020 Jul 18. Epub 2020 Jul 18.

Vedanta Research, Chapel Hill, NC, USA.

Purpose: To understand the influence of the systemic lupus erythematosus (SLE)-related flares on patient's health-related quality of life (HRQoL).

Methods: An online survey included individuals with self-reported physician's diagnosis of SLE or lupus nephritis (LN). Lupus impact tracker (LIT) assessed lupus symptoms and HRQoL, SLE-Family questionnaire measured family role functioning, and Healthy Days Core Module (HDCM) measured overall mental and physical health. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11136-020-02572-9DOI Listing

Kidney Biopsy Findings in Patients with COVID-19.

J Am Soc Nephrol 2020 Jul 17. Epub 2020 Jul 17.

Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York

Background: Coronavirus disease 2019 (COVID-19) is thought to cause kidney injury by a variety of mechanisms. To date, pathologic analyses have been limited to patient reports and autopsy series.

Methods: We evaluated biopsy samples of native and allograft kidneys from patients with COVID-19 at a single center in New York City between March and June of 2020. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1681/ASN.2020060802DOI Listing

Clinical and histological significance of urinary CD11c macrophages in lupus nephritis.

Arthritis Res Ther 2020 Jul 17;22(1):173. Epub 2020 Jul 17.

Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Background: Infiltration of immune cells into the kidney is one of the key features of lupus nephritis (LN). The presence of immune cells in the urine may be used as a non-invasive biomarker of LN. Here, we aimed to analyze the clinicopathologic significance of urinary CD11c macrophages in patients with LN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-020-02265-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368794PMC

Head-to-head comparative pharmacokinetic and biodistribution (PK/BD) study of two dexamethasone prodrug nanomedicines on lupus-prone NZB/WF1 mice.

Nanomedicine 2020 Jul 15;29:102266. Epub 2020 Jul 15.

Department of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address:

HPMA copolymer-based dexamethasone prodrug (P-Dex) and PEG-based dexamethasone prodrug (PEG-Dex, ZSJ-0228) were previously found to passively target the inflamed kidney and provide potent and sustained resolution of nephritis in NZB/WF1 lupus-prone mice. While both prodrug nanomedicines effectively ameliorate lupus nephritis, they have demonstrated distinctively different safety profiles. To explore the underlining mechanisms of these differences, we conducted a head-to-head comparative PK/BD study of P-Dex and PEG-Dex on NZB/WF1 mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nano.2020.102266DOI Listing
July 2020
6.155 Impact Factor

Outcome of biopsy-proven lupus nephritis with low glomerular filtration rate at presentation.

Int J Rheum Dis 2020 Jul 17. Epub 2020 Jul 17.

Department of Nephrology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.

Objectives: Currently, there is limited data regarding the outcomes of lupus nephritis (LN) with moderate to severe renal failure at presentation (defined by low glomerular filtration rate; GFR <30 mL/min).

Methods: Sixty-four patients with biopsy-proven LN and estimated GFR (eGFR) <30 mL/min were prospectively analyzed. Outcome measure of persistently low eGFR, end-stage renal disease (ESRD) or death at 365 days were grouped as Major Adverse Kidney Events (MAKE365). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13907DOI Listing

Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2.

Int J Mol Sci 2020 Jul 14;21(14). Epub 2020 Jul 14.

Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea.

Lupus nephritis (LN) is the most frequent phenotype in patients with systemic lupus erythematosus (SLE) and has a high rate of progression to end-stage renal disease, in spite of intensive treatment and maintenance therapies. Recent evidence suggests that protease-activated receptor-2 (PAR2) is a therapeutic target for glomerulonephritis. In this study, we performed a cell-based high-throughput screening and identified a novel potent PAR2 antagonist, punicalagin (PCG, a major polyphenol enriched in pomegranate), and evaluated the effects of PCG on LN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21144975DOI Listing

Non-lupus full house nephropathy in pediatrics: Case reports

Biomedica 2020 06 15;40(2):220-227. Epub 2020 Jun 15.

Servicio de Reumatología Pediátrica, Hospital Infantil Napoleón Franco Pareja, Cartagena, Colombia.

Full house nephropathy is defined as the simultaneous detection of IgA, IgG, IgM, C3, and C1q deposits by immunofluorescence, usually indicating lupus nephritis. There are patients with this immunofluorescence pattern, but with negative autoantibody serology, which means they cannot be diagnosed with systemic lupus erythematosus. Patients presenting with full house nephropathy but no other criteria for lupus are diagnosed as having nonlupus full house nephropathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7705/biomedica.4863DOI Listing

Autophagy and Glomerular Diseases.

Adv Exp Med Biol 2020 ;1207:481-486

Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases, Beijing, China.

Autophagy is an endogenous and essential process which maintains cellular homeostasis and directs cell fate. The glomerular diseases are one main part of the kidney diseases, often associated with poor clinical outcomes. The regulation of autophagy contributes to the progression of various glomerular diseases, including focal segmental glomerulosclerosis, lupus nephritis, and so on. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-981-15-4272-5_35DOI Listing
January 2020

Systemic lupus erythematosus-myositis overlap syndrome with lupus nephritis.

J Family Med Prim Care 2020 Apr 30;9(4):2104-2106. Epub 2020 Apr 30.

Department of General Medicine, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya, India.

Systemic lupus erythematosus-myositis overlap syndrome is rare with prognostic implications. Reports suggest that systemic lupus erythematosus-myositis overlap syndrome with lupus nephritis has a variable clinical outcome. We report a case of systemic lupus erythematosus-myositis overlap syndrome with lupus nephritis in a 28-year-old female, who presented with facial puffiness, proximal muscle weakness, and proteinuria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jfmpc.jfmpc_186_20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346913PMC

Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies.

Clin Pharmacol 2020 1;12:83-96. Epub 2020 Jul 1.

Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ 07920, USA.

Background: Voclosporin, a more potent derivative of cyclosporine, has been studied extensively in patients with immunologic disorders such as psoriasis, organ transplantation, uvetitis and lupus nephritis. Although better tolerated and safer than cyclosporine, voclosporin is inferior to cyclosporine in treating psoriasis, non-inferior to tacrolimus in organ transplantation and efficacious in treating lupus nephritis.

Methods: The pharmacokinetic dispositions of voclosporin and cyclosporine in central and peripheral compartments were analyzed and correlated with their distinct clinical efficacy and safety profiles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CPAA.S255789DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335848PMC

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.

RMD Open 2020 Jul;6(2)

Section of Musculoskeletal Disease, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK.

Objective: To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of patients with active psoriatic arthritis (PsA).

Methods: This was a phase II, randomised, placebo-controlled, double-blind trial of adults with active PsA (≥3 swollen and ≥3 tender joints and C reactive protein ≥0.3 mg/dL) despite conventional synthetic disease-modifying anti-rheumatic drug, non-steroidal anti-inflammatory drug, and/or oral corticosteroid therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2020-001217DOI Listing

Influence of glutathione S transferase A1 gene polymorphism (-69C > T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis.

Clin Rheumatol 2020 Jul 13. Epub 2020 Jul 13.

Clinical Pathology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.

Objectives: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease. Cyclophosphamide (CYC) is a cytotoxic drug of a narrow therapeutic window that is commonly used in lupus nephritis (LN) treatment. However, 30-40% of patients experience CYC resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-020-05276-0DOI Listing

Hereditary C1 inhibitor deficiency associated with systemic lupus erythematosus.

Lupus 2020 Jul 12:961203320935980. Epub 2020 Jul 12.

Niruj Rheumatology Clinic, Ahmedabad, Gujarat, India.

Here, we report a family with two children (the elder son and younger daughter) diagnosed with juvenile-onset systemic lupus erythematosus (SLE) and the father diagnosed with hereditary angioedema. Serum C1 inhibitor (C1-INH) levels were low, and clinical exome next-generation sequencing detected a frameshift mutation in the gene in all three patients. The mother had neither of the clinical phenotypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203320935980DOI Listing

Risk factors of venous thromboembolism in patients with nephrotic syndrome: a retrospective cohort study.

Nephrol Dial Transplant 2020 Jul 13. Epub 2020 Jul 13.

Department of Pharmacoepidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Background: Nephrotic syndrome is associated with an increased risk of venous thromboembolism (VTE). However, the risk factors of VTE in nephrotic syndrome, other than hypoalbuminemia and severe proteinuria, are not well established. Therefore we aimed to investigate the risk factors of VTE in patients with nephrotic syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ndt/gfaa134DOI Listing